Kapil Bharti

Kapil Bharti

Auto-generated profile, based on publicly available information

Kapil Bharti

Ocular and Stem Cell Translational Research Section, National Eye Institute, NIH

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RSRuchi Sharma
Ruchi Sharma
VKVladimir Khristov
Vladimir Khristov
ARAaron Rising
Aaron Rising
BJBalendu Shekhar Jha
Balendu Shekhar Jha
RDRoba Dejene
Roba Dejene
KBKapil Bharti
Kapil Bharti
A retinal pigment epithelial patch derived from mutation-free pluripotent stem cells shows therapeutic effects in rats and pigs.

5 December 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LKLindsay S. Keir
Lindsay S. Keir
RFRachel Firth
Rachel Firth
LALyndsey Aponik
Lyndsey Aponik
DFDaniel Feitelberg
Daniel Feitelberg
SSSusumu Sakimoto
Susumu Sakimoto
MFMartin Friedlander
Martin Friedlander
Outer retinal and renal glomerular functions rely on specialized vasculature maintained by VEGF that is produced by neighboring epithelial cells, the retinal pigment epithelium (RPE) and podocytes, respectively. Dysregulation of RPE- and podocyte-derived VEGF is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillaris degeneration, and glomerular thrombotic microangiopathy (TMA). Since complement activation and genetic variants in inhibitory complement factor H (CFH) are also features of both ARMD and TMA, we hypothesized that VEGF and CFH interact. Here, we demonstrated that VEGF inhibition decreases local CFH and other complement regulators in the eye and kidney through reduced VEGFR2/PKC-α/CREB signaling. Patient podocytes and RPE cells carrying disease-associated CFH genetic variants had more alternative complement pathway deposits than controls. These deposits were increased by VEGF antagonism, a common wet ARMD treatment, suggesting that VEGF inhibition could reduce cellular complement regulatory capacity. VEGF antagonism also increased markers of endothelial cell activation, which was partially reduced by genetic complement inhibition. Together, these results suggest that VEGF protects the retinal and glomerular microvasculature, not only through VEGFR2-mediated vasculotrophism, but also through modulation of local complement proteins that could protect against complement-mediated damage. Though further study is warranted, these findings could be relevant for patients receiving VEGF antagonists.

6 May 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
DODavide Ortolan
Davide Ortolan
RSRuchi Sharma
Ruchi Sharma
AVAndrei Volkov
Andrei Volkov
AMArvydas Maminishkis
Arvydas Maminishkis
NHNathan A. Hotaling
Nathan A. Hotaling
KBKapil Bharti
Kapil Bharti
Significance: Retinal degenerative diseases affect specific regions of the retinal pigment epithelium (RPE), suggesting the presence of functionally different RPE subpopulations. To identify these subpopulations in human eyes, we generated the first complete morphometric map of the RPE at single-cell resolution using artificial intelligence–based software. We identified five concentric RPE subpopulations, including a ring of RPE cells with cell area similar to macula in the periphery of the eye. Moreover, we found that specific RPE subpopulations are differentially susceptible to monogenic and polygenic retinal diseases. The results obtained here will allow study of molecular and functional RPE differences responsible for regional retinal diseases and will help develop precise cell and gene therapies for specific degenerative eye diseases.

11 July 2016 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
KMKiyoharu J. Miyagishima
Kiyoharu J. Miyagishima
QWQin Wan
Qin Wan
BCBarbara Corneo
Barbara Corneo
RSRuchi Sharma
Ruchi Sharma
MLMostafa R. Lotfi
Mostafa R. Lotfi
KBKapil Bharti
Kapil Bharti
Induced pluripotent stem cells (iPSCs) can be efficiently differentiated into retinal pigment epithelium (RPE), offering the possibility of autologous cell replacement therapy for retinal degeneration stemming from RPE loss. The generation and maintenance of epithelial apical-basolateral polarity is fundamental for iPSC-derived RPE (iPSC-RPE) to recapitulate native RPE structure and function. Presently, no criteria have been established to determine clonal or donor based heterogeneity in the polarization and maturation state of iPSC-RPE. We provide an unbiased structural, molecular, and physiological evaluation of 15 iPSC-RPE that have been derived from distinct tissues from several different donors. We assessed the intact RPE monolayer in terms of an ATP-dependent signaling pathway that drives critical aspects of RPE function, including calcium and electrophysiological responses, as well as steady-state fluid transport. These responses have key in vivo counterparts that together help determine the homeostasis of the distal retina. We characterized the donor and clonal variation and found that iPSC-RPE function was more significantly affected by the genetic differences between different donors than the epigenetic differences associated with different starting tissues. This study provides a reference dataset to authenticate genetically diverse iPSC-RPE derived for clinical applications. Significance: The retinal pigment epithelium (RPE) is essential for maintaining visual function. RPE derived from human induced pluripotent stem cells (iPSC-RPE) offer a promising cell-based transplantation therapy for slowing or rescuing RPE-induced visual function loss. For effective treatment, iPSC-RPE must recapitulate the physiology of native human RPE. A set of physiologically relevant functional assays are provided that assess the polarized functional activity and maturation state of the intact RPE monolayer. The present data show that donor-to-donor variability exceeds the tissue-to-tissue variability for a given donor and provides, for the first time, criteria necessary to identify iPSC-RPE most suitable for clinical application.

11 July 2022 in Experimental Eye Research
Verified
Journal Article
Closed access
KBKapil Bharti
Kapil Bharti
AHAnneke I. den Hollander
Anneke I. den Hollander
ALAparna Lakkaraju
Aparna Lakkaraju
DSDebasish Sinha
Debasish Sinha
DWDavid S. Williams
David S. Williams
PDPatricia D'Amore
Patricia D'Amore

6 January 2020 in Annual Review of Pharmacology and Toxicology
Verified
Journal Article
Closed access
RSRuchi Sharma
Ruchi Sharma
Devika BoseDevika Bose
Devika Bose
AMArvydas Maminishkis
Arvydas Maminishkis
KBKapil Bharti
Kapil Bharti
Pluripotent stem cells (PSCs) are a potential replacement tissue source for degenerative diseases. Age-related macular degeneration (AMD) is a blinding disease triggered by degeneration of the retinal pigment epithelium (RPE), a monolayer tissue that functionally supports retinal photoreceptors. Recently published clinical and preclinical studies have tested PSC-derived RPE as a potential treatment for AMD. Multiple approaches have been used to manufacture RPE cells, to validate them functionally, to confirm their safety profile, and to deliver them to patients either as suspension or as a monolayer patch. Since most of these studies are at an early regulatory approval stage, the primary outcome has been to determine the safety of RPE transplants in patients. However, preliminary signs of efficacy were observed in a few patients. Here, we review the current progress in the PSC-derived RPE transplantation field and provide a comparative assessment of various approaches under development as potential therapeutics for AMD.